text: To gauge the potential clinical utility of targeting both EGFR and HER2 to control growth and radiosensitize human breast cancers, we examined the effect of a dual EGFR/<< HER2 >> inhibitor, [[ GW572016 ]], on the proliferation and radiation response of either EGFR- or HER2-overexpressing human breast cancer cell lines.